Overview

STATEMENT OF NEED

Myelofibrosis is a rare type of myeloproliferative neoplasm—a heterogenous group of hematopoietic disorders—that affects approximately 13,000 individuals in the United States. As symptoms do not typically manifest in early stages, patients with myelofibrosis often present with advanced disease. The presence of comorbidities precludes most from allogeneic stem cell transplant, the only potentially curative treatment option available. Due to the dearth of effective treatment options, therapeutic goals are focused on slowing progression and maintaining quality of life. Median overall survival varies across risk groups, ranging from 15.4 years for patients with low-risk disease to only 1.3 years for those with high-risk disease. Furthermore, up to 20% of myelofibrosis cases transform to acute myeloid leukemia, where the 5-year overall survival rate is only 27%.

TARGET AUDIENCE

Hematology/oncology physicians, oncology advanced practitioners, and other health care professionals involved in the management of patients with myelofibrosis.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Assess predictive and prognostic markers that can rationally inform personalized care planning in myelofibrosis
• Apply emerging data in therapeutic strategies to improve survival and quality of life in patients with myelofibrosis
• Discuss the implications that research advances in myelofibrosis may have for future clinical practice

FACULTY

Srdan Verstovsek, MD, PhD (Chairperson)
Professor, Department of Leukemia
The University of Texas

Raajit Rampal, MD, PhD
Clinical Director, Leukemia Service
Memorial Sloan Kettering Cancer Center

REGISTRATION

There is no fee to participate in or claim CME credit for this activity.

Please note that the i3 Health does not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

Provided by

Physicians

i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN^®, CPHON^®, CBCN^®, AOCNP^®, AOCNS^®, and BMTCN^® renewal candidates may apply 1 ILNA point toward:

• Cancer Continuum
• Diagnosis and Staging
• Disease-Related Biology
• Scientific Basis for Practice
• Survivorship
• Treatment
• Basic Concepts for Transplantation

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Srdan Verstovsek, MD, PhD, discloses that he has served as a consultant for Celgene, Constellation, Incyte, Novartis, Pragmatist, and Sierra. He has also received research support from Blueprint Medicines, Celgene, CTI BioPharma, Genentech, Gilead, Incyte, Novartis, NS Pharma, Promedior, and Roche.

Raajit Rampal, MD, PhD, discloses that he has served as a consultant for Agios, BeyondSpring, Celgene, Jazz, Partner Therapeutics, and Stemline. He has also received research support from Constellation, Incyte, and Stemline.

Ruben A. Mesa, MD, FACP, discloses that he has served on an advisory board or panel for Blueprint Medicines, Celgene, Genentech, La Jolla Pharmaceutical, Novartis, and Sierra. He has also received grants/research support from Abbvie, Bristol Myers Squibb, CTI BioPharma, and Incyte.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by independent educational grants from Celgene and Incyte.

Aggregate participant data will be shared with commercial supporters of this activity.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact i3 Health prior to the live event at 973-928-8085 or This email address is being protected from spambots. You need JavaScript enabled to view it..

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it.